Failing the most vulnerable

Beyond the scientific challenges of paediatric cancer, economic barriers are a key reason why fewer therapies reach children and young people. Sam emphasises the impact of small patient populations, which make clinical trial recruitment harder and delays the time-to-market for new treatments. Additionally, the unfavourable risk-return balance discourages pharmaceutical companies from investing in paediatric oncology.

To address these challenges, we are taking a fresh approach, providing resourcing and funding to deliver new therapeutics for children’s and young people’s cancer.

Read more from Sam